Welcome to

Our Event


Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our Next-gen immune-oncology congress from past 2 years had gathered the professionals across the globe to deliver such latest developments.


Awesome Image

2 DAY EVENT

50 SPEAKERS

250 TICKETS

10 Hours of Networking

Agenda

Full Name *
Email Id *

Company *
Job Title *

Country Code *
Phone Number *

Country *




Advisors



Our Speakers

Eugene	Zhukovsky
Eugene Zhukovsky

CSO

Biomunex Pharmaceuticals

Jeanette	Leusen
Jeanette Leusen

Group Leader, Tumor Immunology

UMC Utrecht

Thomas 	Valerius
Thomas Valerius

Professor-Department of stem cell and immunotherapy

Kiel Life Science

Lindy Durrant
Lindy Durrant

Professor-Cancer Immunotherapy

The University of Nottingham

Sophia N. Karagiannis
Sophia N. Karagiannis

Head of Cancer Antibody Discovery and Immunotherapy

King's College London

Steven Schellings
Steven Schellings

Associate Director Cellular Therapy

Novartis

Matthias Peipp
Matthias Peipp

Professor, Group Leader

University of Kiel

Matthias Friedrich
Matthias Friedrich

Scientific Director

Amgen


Know All Speakers


Event Sponsors

Platinium

Diamond

Gold

Silver

Sponsors & Exhibitors

Official Logistics Partner


Become Sponsor Know All Sponsors


Media Partners


Supporting Association



Submit your Poster Presentation

Venue

London, UK


View on Map
Image Gallery
Loading...